Clinical Trials

Clinical Trials

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.
Cancer Journey:
Cancer Type:
Disease Learning:
Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?". Our first part was by Dr...
Cancer Journey:
Cancer Type:
Disease Learning:
This is the last of six podcasts produced from the two hour program we did in partnership with the LUNGevity Foundation earlier this year in Santa...
Cancer Journey:
Cancer Type:
Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity. In this podcast, my friend...
Cancer Journey:
Cancer Type:

Articles

Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib
Cancer Journey:
Cancer Type:
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.
Cancer Journey:
Cancer Type:
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.
Cancer Journey:
Cancer Type:
Guest post by Dr. Cathy Pietanza, a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York. She specializes in cancers that arise in the lungs and cares for a large number of patients with small cell lung cancer (SCLC).
Cancer Journey:
Cancer Type:
Disease Learning:
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Cancer Journey:
Cancer Type:

Community Forum

No Result Found